Logo

Novartis receives FDA approval for Mayzent (siponimod), the first oral drug to treat secondary progressive MS with active disease

Share this
Novartis receives FDA approval for Mayzent (siponimod), the first oral drug to treat secondary progressive MS with active disease

Novartis receives FDA approval for Mayzent (siponimod), the first oral drug to treat secondary progressive MS with active disease

Share this article on WhatsApp, LinkedIn and Twitter



Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions